About CRISPR Medicine News Global Clinical Trials Database 2.0
The CRISPR Medicine News (CMN) Global Clinical Trials Database 2.0 is manually curated by the CMN Intelligence team and managed by Karen O’Hanlon Court, PhD, Data Intelligence and Infrastructure Management Manager at CMN.
It aims to be the most comprehensive, up-to-date global database of clinical trials involving gene-editing technologies. This includes trials in which gene editing is used to create a therapy (e.g., ex vivo gene-edited cell therapies) as well as trials in which gene editing reagents themselves are administered as the therapeutic (e.g., in vivo gene editing therapies). Every effort is made to include all relevant trials worldwide.
Using the Database
Select the filters of interest to view results in a tabular format. Results update dynamically as filters are selected or removed.
Long-Term Follow-Up (LTFU) Studies
LTFU studies are non-interventional and do not involve administration of a therapeutic. They follow patients who have previously received a gene-editing therapy or gene-edited therapy in another trial(s).
Clinical Data and Data Sources
Where publicly disclosed, clinical data are included under Press Releases, Publications, Clinical Data. This section may contain press releases, news articles, publications (peer-reviewed and non-peer-reviewed), and patents. While we aim to provide trial-specific clinical data, some entries may include candidate-level data from multiple trials.
Information on delivery, target gene, therapeutic candidate and gene-editing modality is compiled from patents, publications, company slide decks and websites, public disclosures, news sources, and occasional communications with sponsors. Some fields may be incomplete due to limited public disclosure.
Database Access for Patients and Clinicians
This database is available with open access (free) and full access (paid) levels, which provide different sets of filters and functionality. This approach is designed to support sustainability while ensuring that patients, patient advocates and clinicians can access relevant clinical trial information. If you are a patient, patient advocate, healthcare professional, or otherwise seeking access to information beyond what is currently available, please contact us here and we will do our best to assist you. If you are interested in full access license options, please request more details here.
---------------------------------
Copyright, Usage & Enforcement
The CRISPR Medicine News (CMN) Global Clinical Trials Database 2.0, including its structure, taxonomy, categorization framework, curation methodology, annotations, written content, design, and presentation, is the intellectual property of CRISPR Medicine News unless otherwise stated.
While individual clinical trial records originate from publicly available sources (including clinical trial registries, publications, press releases, patents, company disclosures, and other public materials), the aggregation, organization, classification, contextualization, and presentation of this information constitute proprietary editorial and analytical work developed by the CMN Intelligence team.
All company names, product names, trademarks, and registered trademarks referenced in the database are the property of their respective owners.
Permitted Use
Open-access content may be viewed and used for personal, educational, clinical, or non-commercial research purposes, provided that CRISPR Medicine News is clearly cited as the source.
Paid-access users may use database content in accordance with their applicable subscription terms.
Restrictions
Without prior written permission from CRISPR Medicine News, users may not:
Reproduce, redistribute, republish, or publicly display substantial portions of the database
Systematically extract, scrape, mine, or harvest database content
Create derivative databases or products based on CMN’s curated structure, annotations, or classifications
Use database content for commercial resale, licensing, competitive intelligence services, or product development
Circumvent technical safeguards or access controls
Enforcement & Remedies
Unauthorized use of the CMN Global Clinical Trials Database 2.0, including systematic extraction, scraping, reproduction, redistribution, republication, or commercial exploitation of substantial portions of the database, may constitute a violation of applicable copyright, database protection, unfair competition, and contract laws.
CRISPR Medicine News reserves the right to pursue all available legal and equitable remedies, including but not limited to:
Injunctive relief to prevent continued unauthorized use
Statutory and/or actual damages as permitted by applicable law
Recovery of legal costs, expenses, and attorneys’ fees
Immediate termination or suspension of database access
Where applicable, violations may be subject to statutory damages under relevant copyright and database protection laws in the user’s jurisdiction.
Accuracy & Disclaimer
While every effort is made to ensure the accuracy and completeness of the database, information is compiled from publicly disclosed sources and may be incomplete, updated, or revised by sponsors or regulatory authorities without notice. CRISPR Medicine News does not guarantee the completeness or ongoing accuracy of all entries and is not responsible for errors, omissions, or changes in publicly disclosed information.
Use of this website and Database is subject to the CRISPR Medicine News Terms of Use & License Agreement.
© 2026 CRISPR Medicine News (CMN). All rights reserved.
